Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion is that acne, alopecia, and hyperhidrosis are common skin issues with various treatments available, and accurate diagnosis is key for effective management.

About 13% of women had idiopathic hirsutism and 8.5% had polycystic ovary syndrome in a group of Iranian women.

Non-binary transgender individuals need personalized hormonal treatments for better well-being and quality of life.

The document concludes with guidance for doctors on diagnosing and treating hirsutism effectively and safely.

Women with PCOS often have hair loss, which is linked to acne or excess body hair but not to worse hormone or metabolic issues.

Low-level laser therapy may improve hair regrowth and thickness for androgenetic alopecia, but more research is needed.

The document concludes that more research is needed to understand excessive hair growth in women with normal hormone levels and regular ovulation.

Insulin resistance is significantly linked to a higher risk of depression in women with PCOS.

Female pattern hair loss diagnosed by scalp appearance, treated with combined therapies and targeted approaches.

Testosterone replacement therapy can prevent men from fathering children and should not be used by those wanting to stay fertile.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Hirsutism is excessive male-pattern hair growth in women, often caused by hormonal imbalances, and requires ongoing treatment to manage.

Early diagnosis and treatment are crucial for preventing permanent hair loss in various scalp conditions, and while new treatments are promising, more research is needed to evaluate their effectiveness.

Stress and alcohol affect brain chemicals differently in rats, mice, and humans, influenced by genetic differences.

Spironolactone is better than placebo for reducing excessive hair growth in women, but its effectiveness for acne is unclear due to small study sizes.

Young women with PCOS have a higher risk of high blood pressure and metabolic syndrome, but these risks may decrease after age 40.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Certain genetic variations are linked to increased androgen levels in PCOS, but more research is needed to understand these connections fully.

Insulin resistance in women with PCOS can lead to serious health issues, but lifestyle changes and certain medications can help manage symptoms.

Caucasian and Asian women with PCOS generally show similar symptoms, except Asian women have less chest hair.

Hirsute women have lower type 2 17β-HSD enzyme levels, which improve with treatment.

The document concludes that using specific tools and tests is essential for identifying the cause of hair loss and deciding on the right treatment.

The document says that understanding the causes of PCOS is important for treatment, especially in distinguishing the syndrome from just having cystic ovaries, and that losing weight is key for obese women with PCOS.

PCOS may start before birth, involves metabolic issues, and can be treated with drugs like metformin and lifestyle changes.

FPHL causes hair loss in women due to genetics and hormones; minoxidil and anti-androgens are treatments, and early intervention is advised.

Many treatments for hair loss lack proper testing and FDA approval, so their effectiveness is uncertain.

The review highlights the need for more research on transgender dermatology, the role of dermatologists in gender affirmation, and the effects of hormone therapy on skin and hair.

Early diagnosis and treatment of PCOS is crucial to reduce emotional distress and health risks.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Some drugs can cause skin and hair color changes, often reversible when the drug is stopped.